Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.

NCT Number	NCT06520176
Lead Sponsor	The Affiliated People's Hospital of Ningbo University Collaborators: First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital
Conditions	Multiple Myeloma, Hematopoietic Stem Cell Mobilization
Enrollment	99 participants
Start Date	2024-08
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-07-25